Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have received a consensus rating of "Buy" from the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $15.67.
A number of research analysts recently weighed in on the stock. Truist Financial started coverage on shares of Solid Biosciences in a research report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 target price for the company. JPMorgan Chase & Co. lowered their target price on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, March 13th. Wedbush started coverage on Solid Biosciences in a report on Friday, December 13th. They set an "outperform" rating and a $16.00 target price on the stock. Chardan Capital restated a "buy" rating and issued a $16.00 price target on shares of Solid Biosciences in a research note on Friday, March 7th. Finally, HC Wainwright boosted their price target on Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday, March 10th.
Get Our Latest Research Report on SLDB
Institutional Investors Weigh In On Solid Biosciences
A number of large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new position in Solid Biosciences during the fourth quarter worth $34,000. Corton Capital Inc. acquired a new stake in shares of Solid Biosciences during the 4th quarter worth about $41,000. Invesco Ltd. acquired a new stake in shares of Solid Biosciences during the 4th quarter worth about $49,000. Sei Investments Co. bought a new stake in shares of Solid Biosciences during the 4th quarter worth about $52,000. Finally, Wells Fargo & Company MN grew its stake in Solid Biosciences by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company's stock valued at $53,000 after buying an additional 2,986 shares during the last quarter. Institutional investors own 81.46% of the company's stock.
Solid Biosciences Trading Up 1.1 %
Shares of NASDAQ SLDB traded up $0.03 during midday trading on Monday, reaching $2.70. The company's stock had a trading volume of 566,026 shares, compared to its average volume of 881,789. The stock has a 50 day simple moving average of $4.38 and a 200-day simple moving average of $4.81. The stock has a market capitalization of $209.23 million, a price-to-earnings ratio of -0.89 and a beta of 2.07. Solid Biosciences has a fifty-two week low of $2.48 and a fifty-two week high of $10.99.
About Solid Biosciences
(
Get Free ReportSolid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Featured Stories
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
